The University of Southampton
University of Southampton Institutional Repository

Platinum-based chemotherapy ‘Rechallenge’ in advanced non-ovarian solid malignancies

Platinum-based chemotherapy ‘Rechallenge’ in advanced non-ovarian solid malignancies
Platinum-based chemotherapy ‘Rechallenge’ in advanced non-ovarian solid malignancies
Platinum-based chemotherapy forms the backbone of treatment for many solid cancers. However, resistance inevitably develops in those with advanced disease. Platinum rechallenge is a well-established concept in the management of ovarian cancer, small cell lung cancer and germ cell tumours. In other solid malignancies there is a lack of quality evidence to support platinum rechallenge, yet it is a widely adopted strategy. Often, patients are within the last year of life, making questions of efficacy, treatment-related toxicity and quality of life critical factors for treatment recommendations. In this overview we appraise the available evidence for platinum rechallenge and strategies being developed to attempt resensitisation of tumours to platinum-based chemotherapy.
Carboplatin, chemotherapy, cisplatin, rechallenge, resistance
0936-6555
e329-e344
Hack, Joanna
a79b6801-0771-4fe7-a632-e3413b6ffe6f
Crabb, Simon
bcd1b566-7677-4f81-8429-3ab0e85f8373
Hack, Joanna
a79b6801-0771-4fe7-a632-e3413b6ffe6f
Crabb, Simon
bcd1b566-7677-4f81-8429-3ab0e85f8373

Hack, Joanna and Crabb, Simon (2022) Platinum-based chemotherapy ‘Rechallenge’ in advanced non-ovarian solid malignancies. Clinical Oncology, 34 (8), e329-e344. (doi:10.1016/j.clon.2022.02.015).

Record type: Article

Abstract

Platinum-based chemotherapy forms the backbone of treatment for many solid cancers. However, resistance inevitably develops in those with advanced disease. Platinum rechallenge is a well-established concept in the management of ovarian cancer, small cell lung cancer and germ cell tumours. In other solid malignancies there is a lack of quality evidence to support platinum rechallenge, yet it is a widely adopted strategy. Often, patients are within the last year of life, making questions of efficacy, treatment-related toxicity and quality of life critical factors for treatment recommendations. In this overview we appraise the available evidence for platinum rechallenge and strategies being developed to attempt resensitisation of tumours to platinum-based chemotherapy.

Text
Accepted revised manuscript - Overview - platinum rechallenge - Accepted Manuscript
Download (536kB)
Text
1-s2.0-S0936655522000991-main - Proof
Restricted to Repository staff only
Request a copy
Text
Overview - platinum rechallenge
Download (536kB)

More information

Accepted/In Press date: 17 February 2022
e-pub ahead of print date: 11 March 2022
Published date: August 2022
Additional Information: Publisher Copyright: © 2022 The Authors
Keywords: Carboplatin, chemotherapy, cisplatin, rechallenge, resistance

Identifiers

Local EPrints ID: 456407
URI: http://eprints.soton.ac.uk/id/eprint/456407
ISSN: 0936-6555
PURE UUID: 9d679b58-65a2-4ddc-bf0c-f5c36d95a8c1
ORCID for Simon Crabb: ORCID iD orcid.org/0000-0003-3521-9064

Catalogue record

Date deposited: 28 Apr 2022 16:33
Last modified: 17 Mar 2024 07:13

Export record

Altmetrics

Contributors

Author: Joanna Hack
Author: Simon Crabb ORCID iD

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×